Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27867003 | 0.92 | HPGD (0.52) | HPGDTSHRSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL10906582 | 0.86 | HTT (0.47) | HPGDTSHRSMN1; SMN2HTT | |
| SCHEMBL6266813 | 0.86 | HTT (0.47) | HPGDTSHRDPP4SMN1; SMN2KMT2A | |
| SCHEMBL7436181 | 0.85 | HPGD (0.62) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL9456344 | 0.85 | HPGD (0.62) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4298321 | 0.84 | HPGD (0.57) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL8508142 | 0.84 | HPGD (0.53) | HPGDDPP4SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL14661808 | 0.84 | HPGD (0.53) | HPGDDPP4SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18956194 | 0.84 | HPGD (0.50) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL9621863 | 0.84 | HTT (0.63) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104402791-B | Preparation method for nebracetam | 河南师范大学 | 2017-02-01 | — | — | CN | claimed |
| CN-104402791-A | Preparation method for nebracetam | UNIV HENAN NORMAL | 2015-03-11 | — | — | CN | claimed |
| EP-0132811-B1 | 1-SUBSTITUTED 4-HYDROXYMETHYL-PYRROLIDINONES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND INTERMEDIATE | BOEHRINGER INGELHEIM KG (DE) | 1988-09-28 | — | — | EP | claimed |
| US-4581364-A | LEARNING ENHANCEMENT | BOEHRINGER INGELHEIM KG (DE) | 1986-04-08 | — | — | US | claimed |
| EP-0132811-A1 | 1-Substituted 4-hydroxymethyl-pyrrolidinones, processes for their preparation, pharmaceutical composition and intermediate | BOEHRINGER INGELHEIM KG (DE) | 1985-02-13 | — | — | EP | claimed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-4812453-A | Use of 1-benzyl-aminoalkyl-pyrrolidinones as antidepressants | BOEHRINGER INGELHEIM KG (DE) | 1989-03-14 | — | — | US | disclosed |
| EP-0132811-B1 | 1-SUBSTITUTED 4-HYDROXYMETHYL-PYRROLIDINONES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND INTERMEDIATE | BOEHRINGER INGELHEIM KG (DE) | 1988-09-28 | — | — | EP | disclosed |
| EP-0280290-A2 | Agent having an antidepressive activity | BOEHRINGER INGELHEIM KG (DE) | 1988-08-31 | — | — | EP | disclosed |
| US-4767759-A | ANTIHYPOXICS | BOEHRINGER INGELHEIM KG (DE) | 1988-08-30 | — | — | US | disclosed |
| EP-0266563-A2 | Use of 1-benzyl-amino-alkyl-pyrrolidinones as antidepressants | BOEHRINGER INGELHEIM KG (DE) | 1988-05-11 | — | — | EP | disclosed |
| US-4581364-A | LEARNING ENHANCEMENT | BOEHRINGER INGELHEIM KG (DE) | 1986-04-08 | — | — | US | disclosed |
| EP-0136658-A2 | -1-Benzyl-aminoalkyl-pyrrolidinones and their addition salts, process for their preparation and pharmaceutical compounds containing them | BOEHRINGER INGELHEIM KG (DE) | 1985-04-10 | — | — | EP | disclosed |
| EP-0132811-A1 | 1-Substituted 4-hydroxymethyl-pyrrolidinones, processes for their preparation, pharmaceutical composition and intermediate | BOEHRINGER INGELHEIM KG (DE) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HPGD 2119/4885TSHR 4209/4885DPP4 378/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | HPGD 2119/4885TSHR 4209/4885DPP4 378/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HPGD 2119/4885TSHR 4209/4885DPP4 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.